A randomized, double-blind, placebo-controlled, crossover, noninferiority clinical trial was developed to test the hypothesis that there is no difference in the effectiveness of ABH gel compared with placebo in cancer patients with nausea. The primary outcome was the difference in nausea score (on a 0-10 scale) at baseline and at 60 minutes in each treatment group. The difference in the ABH gel-treated group compared with placebo was evaluated for noninferiority. Secondary outcomes included the number of vomiting episodes and side effects over time.
In an interview with WebMD, rTMS developer Alvaro Pascual-Leone, MD, PhD, says that the device originally was created as a way to map the language areas of the brain without surgery. While testing the device, he found that it had long-lasting effects on the brain. Depending on how, when, and where in the brain it was used, the rTMS had either a stimulating or calming effect. Taking advantage of these effects, he and other researchers began exploring whether rTMS could be used as an alternative to electroconvulsive therapy (ECT), sometimes called "shock therapy," in patients with severe depression . They have since expanded their studies to try the technique in patients with other psychiatric conditions, and Pascual-Leone finds the Hoffman results intriguing.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.